pharma · Epilepsy · Bipolar 1 Disorder · RAPP
Rapport Therapeutics
Rapport Therapeutics is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker RAPP. Primary therapeutic focus areas include Epilepsy, Bipolar 1 Disorder, Focal Epilepsy, Focal Onset Seizures,
Boston, USA HQ
2022 Founded
94 Employees
Public company Type
RAPP · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boston, USA
- Founded
- 2022
- Employees
- 94
- Programs
- 5
- Drugs
- 1
- Patents
- 1
RAP-219
Phase 3 · small molecule · Focal Seizure
RAP-219 for Focal Seizure is a Phase 3 program (small_molecule) at Rapport Therapeutics with 2 ClinicalTrials.gov record(s).
Internal code RAP-219-FOS-302
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Rapport Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Focal Seizure
- Status
- active
- Trials
- 2